Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06915168 · ClinicalTrials.gov registry record · NA

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

A NA study of Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT06915168: Recruiting NA study of Breast Carcinoma, sponsored by University of Michigan Rogel Cancer Center.

NCT06915168 is a NA study of Breast Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 20 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06915168, a NA study of Breast Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Symptoms sometimes resolve after treatment but in patients who experienced CIPN, symptoms are still present 1 year post-treatment in about two-thirds of patients and 3 years post-treatment in approximately half of the patients. Previous studies indicate patients lack awareness of long-term CIPN symptoms. A decision aid that provides information about permanent CIPN, that helps patients understand their treatment priorities, and prepares them for a discussion with their medical oncologist may lead to improvements in treatment decision making, satisfaction with decision making, and ultimately increase patient's achievement of their treatment goals.

Primary Outcome

Will be assessed using Question #2 on the Awareness, Preparedness, and Confidence Survey.

Conditions Studied

Interventions

  • OTHER Survey Administration
  • OTHER Informational Intervention

Study Locations (1)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-11-13
Est. Completion 2026-01-31
Phase NA

What NCT06915168 shows while recruiting

NCT06915168 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Survey Administration is the first listed.

NCT06915168 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06915168 about?

NCT06915168 is a clinical study titled "CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer". This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used ...

What is the current status of trial NCT06915168?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-11-13. Estimated completion is 2026-01-31.

What conditions does trial NCT06915168 study?

This clinical trial studies the following conditions: Breast Carcinoma.

What interventions are being tested in trial NCT06915168?

The interventions under investigation include: Survey Administration (OTHER), Informational Intervention (OTHER).

Who is sponsoring clinical trial NCT06915168?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06915168 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06915168's enrollment target sits among peer trials

20 100th of 106 higher than 6 of 106 other Breast Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06915168, the US trial registry maintained by the National Library of Medicine. NCT06915168 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.